N
The startup has developed a diagnostic multi-gene expression test that utilizes a patented algorithm to analyze gene activity profiles within the tumor microenvironment. This test enables physicians to predict the risk of relapse and tumor-related mortality in skin cancer patients, providing critical insights for personalized treatment planning.
Updated 3 months ago
Funding
$21.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed a diagnostic multi-gene expression test that utilizes a patented algorithm to analyze gene activity profiles within the tumor microenvironment. This test enables physicians to predict the risk of relapse and tumor-related mortality in skin cancer patients, providing critical insights for personalized treatment planning.